NIH Awards Will Advance HIV Implementation Research in U.S. Communities Pills for HIV pre-exposure prophylaxis, or PrEP. Credit: NIAID NIH has awarded approximately $10 million to support implementation science research to advance the goals of Ending the HIV Epidemic: A Plan for America, which aims to reduce new HIV diagnoses in the United States by at least 90% by 2030. Some of the awards continue and expand on pilot projects funded in 2019. Others support new projects, including several that will focus on reducing barriers to the use of PrEP—a single daily pill to prevent HIV acquisition—among cisgender heterosexual women. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107